Lund, Sweden, May 7 2019
ImmuneBiotech Medical Sweden AB, the probiotic and microbiome company developing and marketing science-based probiotics, is pleased to announce it has received a Phase 1 grant of €50.000 from the European Innovation Council Horizon 2020 SME Instrument program.
The grant will be used to investigate the business feasibility of ImmuneBiotech’s probiotic product GutMagnificTM in Myalgic Encephalomyelitis, also called Chronic Fatigue Syndrome (ME/CFS). GutMagnificTM is a super-consortium of five probiotic strains scientifically designed to address the underlying key causes of Irritable Bowel Syndrome (IBS). The product also has potential in other conditions such as ME/CFS, which is a debilitating, multi system disease, characterized by unexplained persistent and relapsing fatigue and a combination of accompanying symptoms like IBS. The FDA has described this condition as “serious and life-threatening” with no current treatments. The global prevalence is between 0.2-1%, a higher prevalence than many chronic inflammatory conditions and cancer forms.
The EU selected ImmuneBiotech out of 2 822 applications based on criteria such as the high need for the innovation, a highly innovative solution that goes beyond the start of art, and the excellent experience of our team.
“I’m extremely pleased that ImmuneBiotech was selected by the European Commission. This is another external proof that our 15 years of experience in probiotics, immunology, microbiology and research on the gut-brain-axis is paying off in highly innovative probiotic products.” said Shahram Lavasani, CEO of ImmuneBiotech.